Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: A double-blind, placebo-controlled, prospective trial

Arthritis and Rheumatism

Volumn 62, Issue 5, 2010, Pages 1298-1307

  Carter, J D ^a   Espinoza, L R ^b   Inman, R D ^c   Sneed, K B ^a   Ricca, L R ^a   Vasey, F B ^a   Valeriano, J ^a   Stanich, J A ^d   Oszust, C ^d   Gerard, H C ^d   Hudson, A P ^d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Department of Pathology   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CORTICOSTEROID; DOXYCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RIFAMPICIN;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MALE; NAUSEA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RASH; REACTIVE ARTHRITIS; REMISSION; UPPER RESPIRATORY TRACT INFECTION; VAGINA CANDIDIASIS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTITUBERCULAR; ARTHRITIS, REACTIVE; AZITHROMYCIN; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; CHLAMYDOPHILA PNEUMONIAE; CHRONIC DISEASE; DNA, BACTERIAL; DOUBLE-BLIND METHOD; DOXYCYCLINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JOINTS; MALE; MIDDLE AGED; PLACEBOS; PROSPECTIVE STUDIES; RIFAMPIN; TREATMENT OUTCOME;

EID: 77951710437     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27394     Document Type: Article

References (49)

1. Carter JD, Hudson AP. Reactive arthritis: clinical aspects and medical management. Rheum Dis Clin North Am 2009;35:21-44.
2. Braun J, Laitko S, Treharne J, Eggens U, Wu P, Distler A, et al. Chlamydia pneumoniae - a new causative agent of reactive arthritis and undifferentiated oligoarthritis. Ann Rheum Dis 1994;53: 100-105 (Pubitemid 24087361)
3. Hannu T, Puolakkainen M, Leirisalo-Repo M. Chlamydia pneumoniae as a triggering infection in reactive arthritis. Rheumatology (Oxford) 1999;38:411-414 (Pubitemid 29507124)
4. Manavi K. A review on infection with Chlamydia trachomatis. Best Pract Res Clin Obstet Gynaecol 2006;20:941-951
5. Miyashita N, Niki Y, Nakajima M, Fukano H, Matsushima T. Prevalence of asymptomatic infection with Chlamydia pneumoniae in subjectively healthy adults. Chest 2001;119:1416-1419 (Pubitemid 32686023)
6. Carter JD, Gerard HC, Espinoza LR, Ricca LR, Valeriano J, Snelgrove J, et al. Chlamydiae as etiologic agents in chronic undifferentiated spondylarthritis. Arthritis Rheum 2009;60:1311-1316
7. Braun J, Tuszewski M, Eggens U, Mertz A, Schauer-Petrowskaja C, Doring E, et al. Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. I. Screening of synovial fluid samples of patients with spondyloarthropathies and other arthritides. J Rheumatol 1997;24:1092-1100
8. Granfors K, Jalkanen S, Toivanen P, Koski J, Lindberg AA. Bacterial lipopolysaccharide in synovial fluid cells in Shigella triggered reactive arthritis. J Rheumatol 1992:19:500.
9. Nikkari S, Merilahti-Palo R, Saario R, Soderstrom KO, Granfors K, Skurnik M, et al. Yersinia-triggered reactive arthritis: use of polymerase chain reaction and immunocytochemical staining in the detection of bacterial components from synovial specimens. Arthritis Rheum 1992;35:682-687
10. Nikkari S, Rantakokko K, Ekman P, Mottonen T, Leirisalo-Repo M, Virtala M, et al. Salmonella-triggered reactive arthritis: use of polymerase chain reaction, immunocytochemical staining, and gas chromatography-mass spectrometry in the detection of bacterial components from synovial fluid. Arthritis Rheum 1999;42:84-89 (Pubitemid 29042574)
11. Taylor-Robinson D, Gilroy CB, Thomas BJ, Keat AC. Detection of Chlamydia trachomatis DNA in joints of reactive arthritis patients by polymerase chain reaction. Lancet 1992;340:81-82
12. Gerard HC, Branigan PJ, Schumacher HR Jr, Hudson AP. Synovial Chlamydia trachomatis in patients with reactive arthritis/ Reiter's syndrome are viable but show aberrant gene expression. J Rheumatol 1998;25:734-742
13. Gerard HC, Schumacher HR, El-Gabalawy H, Goldbach-Mansky R, Hudson AP. Chlamydia pneumoniae present in the human synovium are viable and metabolically active. Microb Pathog 2000;29:17-24.
14. Gaston JS, Cox C, Granfors K. Clinical and experimental evidence for persistent Yersinia infection in reactive arthritis. Arthritis Rheum 1999;42:2239-2242 (Pubitemid 30263612)
15. Gerard HC, Wang Z, Whittum-Hudson JA, El-Gabalawy H, Goldbach-Mansky R, Bardin T, et al. Cytokine and chemokine mRNA produced in synovial tissue chronically infected with Chlamydia trachomatis and C. pneumoniae. J Rheumatol 2002;29: 1827-1835 (Pubitemid 34988688)
16. Gerard HC, Whittum-Hudson JA, Schumacher HR, Hudson AP. Differential expression of three Chlamydia trachomatis hsp60-encoding genes in active vs. persistent infections. Microb Pathog 2004;36:35-39
17. Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, Mottonen T, Hakola M, Korpela M, et al. Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis. Ann Rheum Dis 2000;59:565-570 (Pubitemid 30445837)
18. Kvien TK, Gaston JS, Bardin T, Butrimiene I, Dijkmans BA, Leirisalo-Repo M, et al. Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. Ann Rheum Dis 2004;63:1113-1119 (Pubitemid 39120363)
19. Sieper J, Fendler C, Laitko S, Sorensen H, Gripenberg-Lerche C, Hiepe F, et al. No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebocontrolled study. Arthritis Rheum 1999;42:1386-1396 (Pubitemid 30265596)
20. Wakefield D, McCluskey P, Verma M, Aziz K, Gatus B, Carr G. Ciprofloxacin treatment does not influence course or relapse rate of reactive arthritis and anterior uveitis. Arthritis Rheum 1999;42: 1894-1897 (Pubitemid 30257754)
21. Dreses-Werringloer U, Padubrin I, Jurgens-Saathoff B, Hudson AP, Zeidler H, Kohler L. Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro. Antimicrob Agents Chemother 2000;44:3288-3297 (Pubitemid 33009485)
22. Dreses-Werringloer U, Padubrin I, Zeidler H, Kohler L. Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro. Antimicrob Agents Chemother 2001;45:3001-3008 (Pubitemid 32988820)
23. Suchland RJ, Geisler WM, Stamm WE. Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrob Agents Chemother 2003;47:636-642
24. Morrissey I, Salman H, Bakker S, Farrell D, Bebear CM, Ridgway G. Serial passage of Chlamydia spp. in sub-inhibitory fluoroquinolone concentrations. J Antimicrob Chemother 2002;49:757-761 (Pubitemid 34537635)
25. Lauhio A, Leirisalo-Repo M, Lahdevirta J, Saikku P, Repo H. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum 1991;34:6-14.
26. Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, Mottonen T, Hakola M, Korpela M, et al. Effect of three month course of ciprofloxacin on the late prognosis of reactive arthritis. Ann Rheum Dis 2003;62:880-884 (Pubitemid 37026500)
27. Cruz J, Mosquera JA, Romero Pontevedra S. Long-term evaluation (7 years) of antimicrobial therapy in early reactive arthritis (ERea) [abstract]. Arthritis Rheum 1999;42 Suppl:S334.
28. Putschky N, Pott HG, Kuipers JG, Zeidler H, Hammer M, Wollenhaupt J. Comparing 10-day and 4-month doxycycline courses for treatment of Chlamydia trachomatis-reactive arthritis: a prospective, double-blind trial. Ann Rheum Dis 2006;65:1521-1524 (Pubitemid 44629134)
29. Engel JN, Pollack J, Perara E, Ganem D. Heat shock response of murine Chlamydia trachomatis. J Bacteriol 1990;172:6959-6972
30. Zugel U, Kaufmann SH. Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Clin Microbiol Rev 1999;12:19-39. (Pubitemid 29055952)
31. Qoronfleh MW, Gustafson JE, Wilkinson BJ. Conditions that induce Staphylococcus heat shock proteins also inhibit autolysis. FEMS Microbiol Lett 1998;166:103-107
32. Dean D, Powers VC. Persistent Chlamydia trachomatis infections resist apoptotic stimuli. Infect Immun 2001;69:2442-2447 (Pubitemid 32239715)
33. Airenne S, Surcel HM, Tuukkanen J, Leinonen M, Saikku P. Chlamydia pneumoniae inhibits apoptosis in human epithelial and monocyte cell lines. Scand J Immunol 2002;55:390-398 (Pubitemid 34429795)
34. Curry AJ, Portig I, Goodall JC, Kirkpatrick PJ, Gaston JS. T lymphocyte lines isolated from atheromatous plaque contain cells capable of responding to Chlamydia antigens. Clin Exp Immunol 2000;121:261-269 (Pubitemid 30659763)
35. Carter JD, Valeriano J, Vasey FB. Doxycycline versus doxycycline and rifampin in undifferentiated spondyloarthropathy, with special reference to Chlamydia-induced arthritis: a prospective, randomized 9-month comparison. J Rheumatol 2004;31:1973-1980 (Pubitemid 39336722)
36. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al, and the European Spondylarthropathy Study Group. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-1227
37. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-145
38. Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondylarthropathy: a randomized, multicenter, double-blind, placebocontrolled study. Arthritis Rheum 1995;38:618-627
39. Schumacher HR Jr, Kulka JP. Needle biopsy of the synovial membrane - experience with the Parker-Pearson technique. N Engl J Med 1972;286:416-419
40. Stephens RS, Kalman S, Lammel C, Fan J, Marathe R, Aravind L, et al. Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science 1998;282:754-759 (Pubitemid 28489390)
41. Kalman S, Mitchell W, Marathe R, Lammel C, Fan J, Hyman RW, et al. Comparative genomes of Chlamydia pneumoniae and C trachomatis. Nat Genet 1999;21:385-389 (Pubitemid 29159574)
42. Clegg DO, Reda DJ, Weisman MH, Cush JJ, Vasey FB, Schumacher HR Jr, et al. Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome): a Department of Veterans Affairs cooperative study. Arthritis Rheum 1996;39:2021-2027
43. Jaspersen D. Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management. Drug Saf 2000;22:237-249 (Pubitemid 30157584)
44. Saiman L. The use of macrolide antibiotics in patients with cystic fibrosis. Curr Opin Pulm Med 2004;10:515-523 (Pubitemid 39441447)
45. Siala M, Gdoura R, Younes M, Fourati H, Cheour I, Meddeb N, et al. Detection and frequency of Chlamydia trachomatis DNA in synovial samples from Tunisian patients with reactive arthritis and undifferentiated oligoarthritis. FEMS Immunol Med Microbiol 2009;55:178-186
46. Dowell SF, Peeling RW, Boman J, Carlone GM, Fields BS, Guarner J, et al, and the C. pneumoniae Workshop Participants. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001;33:492-503.
47. Peeling RW, Wang SP, Grayston JT, Blasi F, Boman J, Clad A, et al. Chlamydia pneumoniae serology: interlaboratory variation in microimmunofluorescence assay results. J Infect Dis 2000;181 Suppl 3:S426-9.
48. Ozanne G, Lefebvre J. Specificity of the microimmunofluorescence assay for the serodiagnosis of Chlamydia pneumoniae infections. Can J Microbiol 1992;38:1185-1189 (Pubitemid 23030253)
49. Haralambieva I, Iankov I, Petrov D, Ivanova R, Kamarinchev B, Mitov I. Cross-reaction between the genus-specific lipopolysaccharide antigen of Chlamydia spp. and the lipopolysaccharides of Porphyromonas gingivalis, Escherichia coli O119 and Salmonella newington: implications for diagnosis. Diagn Microbiol Infect Dis 2001;41:99-106.